Masimo announced preliminary fourth-quarter 2025 revenue of $420 million, surpassing consensus estimates of $405 million by 3.7%. The company also reported adjusted EPS of $0.45 for the quarter, beating the Street estimate of $0.42 by 7.1%. For the full year, Masimo posted preliminary revenue of $1.70 billion, 3.0% above the consensus forecast of $1.65 billion, and adjusted EPS of $1.80, topping the $1.75 consensus by 2.9%. Management attributed the outperformance to sustained momentum in core healthcare monitoring products, particularly in hospital pulse oximetry and patient-worn continuous monitoring systems. Despite the robust results, Masimo’s stock declined roughly 5% in after-hours trading, as investors appeared to have priced in the beat or sought greater clarity on guidance for 2026.

At the J.P. Morgan Healthcare Conference, CEO Catherine Szyman highlighted Masimo’s position as a global leader in patient monitoring, serving over 200 million patients annually across more than 150 countries. She underscored the company’s $1.5 billion in trailing-12-month revenue and its engineering team of over 350 professionals, noting a retention rate among engineers that ranks among the highest in the medical device industry. Szyman also emphasized Masimo’s installed base of 2.6 million monitoring units worldwide and praised the resilience of its supply chain through COVID-related disruptions. These statistics reinforce Masimo’s scale and operational stability, factors management believes will drive further market share gains and margin expansion in the years ahead.